XBIO

Xenetic Biosciences, Inc. (XBIO) | Rumor.io

Xenetic Biosciences

XBIO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,840

Bullish sentiment (50-day avg)94%

Price to earnings ratio-1.46

Market capitalization5.5M

Earnings per share-1.15

Dividend yield (TTM)—

Revenue (annual)3M

Net income (annual)-2.7M

Social

What share of all stock conversation is about XBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Sep 16

Xenetic Biosciences and Santersus AG have entered into a definitive share exchange agreement, creating a global leader in NET-targeting therapeutics.
The combined company will be renamed Santersus Bio, with Santersus shareholders owning approximately 85% and Xenetic shareholders retaining about 15%.
The deal brings four clinical programs, including pivotal-stage assets in sepsis and lupus, with each holding FDA Breakthrough Device Designation.

Generated by AI

Sentiment

Of the messages about XBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +50	60% -40	91.22% -4.9
Bearish	—	0% -50	40% new	8.78% +4.9

Bullish· Oct 8

$XBIO has been steadily increasing, with a 150% rise in value, and is holding its weekly structure level into new highs.
This biopharmaceutical company has a strong match to top faders and hasn't given a technical reason to short yet, making it a high-probability chance for traders.
$XBIO's innovative DNase platform is attracting investment, and the company's clinical collaborations and strategic MOUs have driven a 31% surge in the stock.

Bearish· Oct 8

The RSI for $XBIO is overbought, suggesting a pullback to $5-10.
$XBIO's recent surge lacks a clear catalyst, indicating a potential retracement to $5-10.
$XBIO's price action resembles a pump and dump scheme, with traders experiencing FOMO and potential losses.

Generated by AI

Topics

Of the messages about XBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	42.4%
Analysts	—	—	0%	21.47%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	8.23%
Technical Analysis	—	—	0%	27.91%

Announcements· Sep 16

Xenetic Biosciences ($XBIO) will acquire Santersus AG in an all-stock deal, with Santersus shareholders owning approximately 85% of the combined company.
The merger will create a global leader in NET-targeting therapeutics, with four clinical-stage programs, including pivotal-stage assets in sepsis and lupus with FDA Breakthrough Device Designation.
The combined company, renamed Santersus Bio, will have a pipeline spanning critical care, autoimmune diseases, and lymphoma, with a focus on targeting neutrophil extracellular traps (NETs).

Technical Analysis· Aug 2

The weekly trend line for $XBIO is still on track for steady growth, with the stock settling around $5 without any new information.
A break of $5.85 is expected to see a break of $6, as it is the 52-week high and a strong resistance line.
The stock has formed a bull flag in the 30-minute chart, with a potential load-up opportunity after confirmation.

Generated by AI

Community

Of the messages about XBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	12.66%	9.66%
Newcomers	100%	100%	87.34%	90.34%

Regulars· Apr 27

Xenetic Biosciences, Inc. has entered an exclusive license and sublicense agreement with CLS Therapeutics, which includes an upfront payment of $500,000 and the potential for up to $13 million in future milestones.
The company's quarterly revenue growth rate YoY is 201.30%, ranking 254 out of 5722 companies in the database.
The stock price may climb as it broke lower Bollinger Band, and the RSI indicator has exited the overbought zone, indicating a potential downtrend reversal.

Newcomers· Sep 16

Newcomers to discussing $XBIO are focused on the company's recent merger with Santersus AG, which will create a global leader in NET-targeting therapeutics.
The acquisition will result in Xenetic Biosciences shareholders owning only 15% of the combined company, with Santersus holders owning approximately 85%.
The combined company, Santersus Bio, will focus on targeting neutrophil extracellular traps (NETs) in various diseases, including sepsis and lupus, with four clinical programs already in place.

Generated by AI

The proposed transaction would create a Nasdaq-listed company focused on NET-targeting therapies, combining four clinical programs while transferring majority ownership to Santersus shareholders. Key Investor TakeawaysXenetic Biosciences (NASDAQ:XBIO) has signed a definitive share exchange agreement to acquire privately held Santersus AG in an all-stock transaction.

13d agoYahoo Finance

Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition

13d agoBenzinga

Xenetic Biosciences to acquire Santersus in all-stock deal

14d agoInvesting.com

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

The combined company is expected to continue to trade on the Nasdaq Capital Market as Santersus Bio, Inc."The Proposed Transaction is expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on a single high-impact therapeutic target: neutrophil extracellular traps, or NETs.

14d agoYahoo Finance

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

1mo agoYahoo Finance

Xenetic Biosciences: Q2 Earnings Snapshot

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

1mo agofinance.yahoo.com

Also Discussed

Investors talking about XBIO also mention

#	Name	Attention
1	NanoVibronix, Inc.NAOV	0%0
2	Avalon Holdings Corp. Class A Common StockAWX	0%new
3	Bridgeline Digital IncBLIN	0%new
4	Viveve Medical Inc.VIVE	0%0
5	Repay Holdings Corporation Class A Common StockRPAY	0%0
6	Achieve Life Sciences, Inc.ACHV	0%new
7	OBLN - Obalon Therapeutics, Inc.	——
8	Arcadia Biosciences Inc.RKDA	0.01%0
9	STAF - Staffing 360 Solutions, Inc.	——
10	Bio-Path Holdings Inc.BPTH	0%0

Xenetic Biosciences, Inc.

Healthcare
Biotechnology

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing immune-oncology technologies for hard-to-treat cancers. The company’s current work centers on its DNase platform, which is designed to target neutrophil extracellular traps (NETs) and support the effectiveness of existing cancer treatments such as immunotherapies. Xenetic Biosciences is also advancing product candidates including XBIO-015 and XBIO-020 for pancreatic carcinoma and other solid tumors, along with platform technologies such as PolyXen and XCart. In addition to oncology, the company has programs that address related therapeutic areas, including anemia in chronic kidney disease through ErepoXen. Headquartered in Framingham, Massachusetts, Xenetic Biosciences serves as a specialized biotechnology player with a pipeline oriented toward novel treatment approaches across oncology and selected adjacent indications.

Website

Location

945 Concord Street

Framingham, MA, 01701

United States

Social

What share of all stock conversation is about XBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Sep 16

Xenetic Biosciences and Santersus AG have entered into a definitive share exchange agreement, creating a global leader in NET-targeting therapeutics.
The combined company will be renamed Santersus Bio, with Santersus shareholders owning approximately 85% and Xenetic shareholders retaining about 15%.
The deal brings four clinical programs, including pivotal-stage assets in sepsis and lupus, with each holding FDA Breakthrough Device Designation.

Generated by AI

Sentiment

Of the messages about XBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +50	60% -40	91.22% -4.9
Bearish	—	0% -50	40% new	8.78% +4.9

Bullish· Oct 8

$XBIO has been steadily increasing, with a 150% rise in value, and is holding its weekly structure level into new highs.
This biopharmaceutical company has a strong match to top faders and hasn't given a technical reason to short yet, making it a high-probability chance for traders.
$XBIO's innovative DNase platform is attracting investment, and the company's clinical collaborations and strategic MOUs have driven a 31% surge in the stock.

Bearish· Oct 8

The RSI for $XBIO is overbought, suggesting a pullback to $5-10.
$XBIO's recent surge lacks a clear catalyst, indicating a potential retracement to $5-10.
$XBIO's price action resembles a pump and dump scheme, with traders experiencing FOMO and potential losses.

Generated by AI

Topics

Of the messages about XBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	42.4%
Analysts	—	—	0%	21.47%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	8.23%
Technical Analysis	—	—	0%	27.91%

Announcements· Sep 16

Xenetic Biosciences ($XBIO) will acquire Santersus AG in an all-stock deal, with Santersus shareholders owning approximately 85% of the combined company.
The merger will create a global leader in NET-targeting therapeutics, with four clinical-stage programs, including pivotal-stage assets in sepsis and lupus with FDA Breakthrough Device Designation.
The combined company, renamed Santersus Bio, will have a pipeline spanning critical care, autoimmune diseases, and lymphoma, with a focus on targeting neutrophil extracellular traps (NETs).

Technical Analysis· Aug 2

The weekly trend line for $XBIO is still on track for steady growth, with the stock settling around $5 without any new information.
A break of $5.85 is expected to see a break of $6, as it is the 52-week high and a strong resistance line.
The stock has formed a bull flag in the 30-minute chart, with a potential load-up opportunity after confirmation.

Generated by AI

Community

Of the messages about XBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	12.66%	9.66%
Newcomers	100%	100%	87.34%	90.34%

Regulars· Apr 27

Xenetic Biosciences, Inc. has entered an exclusive license and sublicense agreement with CLS Therapeutics, which includes an upfront payment of $500,000 and the potential for up to $13 million in future milestones.
The company's quarterly revenue growth rate YoY is 201.30%, ranking 254 out of 5722 companies in the database.
The stock price may climb as it broke lower Bollinger Band, and the RSI indicator has exited the overbought zone, indicating a potential downtrend reversal.

Newcomers· Sep 16

Newcomers to discussing $XBIO are focused on the company's recent merger with Santersus AG, which will create a global leader in NET-targeting therapeutics.
The acquisition will result in Xenetic Biosciences shareholders owning only 15% of the combined company, with Santersus holders owning approximately 85%.
The combined company, Santersus Bio, will focus on targeting neutrophil extracellular traps (NETs) in various diseases, including sepsis and lupus, with four clinical programs already in place.

Generated by AI

Xenetic Biosciences

Social

Sep 16

Bullish· Oct 8

Bearish· Oct 8

Announcements· Sep 16

Technical Analysis· Aug 2

Regulars· Apr 27

Newcomers· Sep 16

Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake

Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition

Xenetic Biosciences to acquire Santersus in all-stock deal

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences: Q2 Earnings Snapshot

Also Discussed

Xenetic Biosciences, Inc.

Company Information

Location

Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake

Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition

Xenetic Biosciences to acquire Santersus in all-stock deal

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences: Q2 Earnings Snapshot

Also Discussed

Social

Sep 16

Bullish· Oct 8

Bearish· Oct 8

Announcements· Sep 16

Technical Analysis· Aug 2

Regulars· Apr 27

Newcomers· Sep 16